scholarly journals The role of serum erythropoietin level andjak2v617f allele burden in the diagnosis of polycythaemia vera

2014 ◽  
Vol 167 (3) ◽  
pp. 411-417 ◽  
Author(s):  
Àgueda Ancochea ◽  
Alberto Álvarez-Larrán ◽  
Cristian Morales-Indiano ◽  
Francesc García-Pallarols ◽  
Luz Martínez-Avilés ◽  
...  
Keyword(s):  
Polycythaemia Vera ◽  
Allele Burden ◽  
Serum Erythropoietin Level ◽  
Serum Erythropoietin ◽  
Erythropoietin Level

scholarly journals Saphenous Vein Graft Disease Is Associated with a Low Serum Erythropoietin Level

2015 ◽  
Vol 24 (6) ◽  
pp. 544-547 ◽  
Author(s):  
Ibrahim Kocaoglu ◽  
Ugur Arslan ◽  
Yavuzer Koza ◽  
Mustafa M�cahit Balci ◽  
Gizem �elik ◽  
...  
Keyword(s):  
Saphenous Vein ◽  
Vein Graft ◽  
Saphenous Vein Graft ◽  
Vein Graft Disease ◽  
Serum Erythropoietin Level ◽  
Graft Disease ◽  
Serum Erythropoietin ◽  
Saphenous Vein Graft Disease ◽  
Erythropoietin Level ◽  
Low Serum

Erythroid response (ER) rates in myelodysplastic syndromes (MDS) patients treated with epoetin alfa (EPO): A meta-analysis using the International Working Group criteria (IWGc) for MDS response

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 6572-6572
Author(s):  
V. Moyo ◽  
P. Lefebvre ◽  
M. S. Duh ◽  
A. Bourezak ◽  
B. Yektashenas ◽  
...  
Keyword(s):  
Data Extraction ◽  
Meta Analysis ◽  
Refractory Anemia ◽  
Regression Analyses ◽  
Epoetin Alfa ◽  
Erythroid Response ◽  
Serum Erythropoietin Level ◽  
Study Characteristics ◽  
Serum Erythropoietin ◽  
Erythropoietin Level

6572 Background: Refractory anemia is a clinical hallmark of MDS. The most consistently used therapy for this anemia is EPO. Prior to the introduction of IWGc in 1997, ER rates varied substantially between studies. The present meta-analysis was undertaken to compare ER rates in studies of EPO-treated patients in MDS when defined by either IWGc or non-IWGc. Methods: A systematic review and data extraction of studies published from 1990–2005 in MDS patients treated with EPO was performed and yielded 21 studies evaluating a total of 895 patients. Pooled estimates of ER rates, stratified by IWGc, were calculated using random-effects meta-analysis methods, which incorporated both between- and within-study variations. Univariate meta-regression analyses were conducted to identify study characteristics that were significant determinants of ER rate. Results: Ten studies (604 patients) used the IWGc to define ER (overall, major, minor), while 11 studies (291 patients) used other definitions. Mean age for all patients was 70.6 years; 45% women. Mean baseline (BL) serum erythropoietin level and proportion of patients with refractory anemia or refractory anemia with ringed sideroblasts were comparable between studies; however, the proportion of transfusion-dependent patients at BL was lower in the IWG studies vs the non-IWG studies (36% vs. 84%, respectively, p<.001). The pooled estimate of ER rate was significantly higher for the IWG studies compared to the non-IWG studies (50.5%, 95% CI: 38.6%-62.3% vs. 27.8%, 95% CI: 22.7%-32.8% respectively, p=.002). Among patients in the IWG studies who achieved an ER, 62% (188/305) achieved a major ER. Studies reporting mean BL serum erythropoietin level <400mU/mL, <65% of patients transfusion-dependent at BL and use of subcutaneous EPO were found to be associated with higher ER rates. Conclusions: This meta-analysis of MDS patients treated with EPO demonstrates significantly higher ER rates in studies utilizing IWGc. These findings may be due to more refined definitions of ER and MDS diagnostic criteria as well as improvement in the management of anemia. [Table: see text]

scholarly journals THE RELATIONSHIP OF SERUM ERYTHROPOIETIN LEVEL WITH CORONARY COLLATERAL DEVELOPMENT

2010 ◽  
Vol 55 (10) ◽  
pp. A153.E1439
Author(s):  
Asife Sahinarslan ◽  
Ridvan Yalcin ◽  
Sinan Kocaman ◽  
Salih Topal ◽  
Ugur Ercin ◽  
...  
Keyword(s):  
Collateral Development ◽  
Coronary Collateral ◽  
Serum Erythropoietin Level ◽  
Relationship Of ◽  
The Relationship ◽  
Serum Erythropoietin ◽  
Erythropoietin Level

Serum erythropoietin level in anemic cancer patients

1999 ◽  
Vol 35 ◽  
pp. S105
Author(s):  
M. Özgüroglu ◽  
G. Demir ◽  
F. Demirelli ◽  
N. Molinas-Mandel ◽  
E. Büyükünal ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Serum Erythropoietin Level ◽  
Serum Erythropoietin ◽  
Erythropoietin Level

scholarly journals Transgenic Expression of JAK2V617F Causes Myeloproliferative Disorders in Mice.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2527-2527
Author(s):  
Shu Xing ◽  
Zhizhuang Joe Zhao
Keyword(s):  
Transgenic Mice ◽  
Myeloproliferative Disorders ◽  
Extramedullary Hematopoiesis ◽  
Transgenic Expression ◽  
Cell Counts ◽  
Serum Erythropoietin Level ◽  
Hyper Sensitivity ◽  
Serum Erythropoietin

Abstract Recently, an acquired mutation of tyrosine kinase JAK2 was found in most patients with myeloproliferative disorders (MPDs) including polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis. We have generated transgenic mice expressing the mutation enzyme, JAK2V617F, in the hematopoietic system driven by the promoter of the vav gene. The mice are viable and fertile. One line of the transgenic mice expressed a lower level of JAK2V617F and displayed elevated blood cell counts, while the other line expressed a higher level of JAK2V617F and exhibited a marked increase in blood counts and developed phenotypes that closely resembled human ET and PV. The latter line of mice also developed marrow and spleen fibrosis as the animal aged. In general, the transgenic mice had megakaryocytic hyperplasia in the bone morrow and extramedullary hematopoiesis resulting in splenomegaly, and their serum erythropoietin level was also significantly reduced. In vitro colony assays demonstrated that transgenic mice possessed an increased number of hematopoietic progenitor cells in peripheral blood, spleen, and bone marrow and that these cells displayed hyper-sensitivity to growth factors and cytokines. The data prove that JAK2V617F is a cause of MPDs. Our study thus provides a permanent mouse system for further study to define the pathological role of JAK2V617F and to develop treatment for MPDs.

Sign in / Sign up

Export Citation Format

Share Document